Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients

作者：G. Abu-Zeinah, Anthony M. Hunter, J. Shatzel, Abdulraheem M. Yacoub, Albert Qin, Hung-Lun Chien, R. Mesa · 发表于：Blood neoplasia · 年份：2025 · DOI：10.1016/j.bneo.2025.100167 · 被引用次数：5 · 研究领域：Medicine

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by clonal expansion of hematopoietic stem and progenitor cells and elevated red blood cell mass, with associated symptoms and risks of thrombosis and disease progression. 1 Treatment almost always involves low-dose aspirin and/or phlebotomy, but cytoreductive therapy is not always instituted. High-risk patients, that is, those aged ≥ 60 years and/or with prior thrombosis, and symptomatic low-risk patients require cytoreductive therapy to mitigate symptoms and/or lower the risk of disease-related complications. 2 Cytoreductive therapy has many potential benefits but may cause adverse events (AEs) that influence treatment decisions. In this real-world study, we evaluate the cytoreductive therapy choices and the AEs associated with the 3 established cytoreductive therapies for PV: hydroxyurea (HU), interferon alfa (IFN-α )–based therapies (mainly peginterferon alfa-2a and the newest approved ropeginterferon alfa-2b [ropeg]), and ruxolitinib (rux).